ESR1 and breast carcinoma: Our study evaluating the NCDB data demonstrates that oncologists are already obtaining RS assay in approximately 1 in 5 node positive, ER+/HER2− negative breast cancer patients and are using the RS results to tailor treatment recommendations, in parallel to ongoing prospective randomized trials.